Guardian Pharmacy Services (NYSE:GRDN) Upgraded at Zacks Research

Zacks Research upgraded shares of Guardian Pharmacy Services (NYSE:GRDN) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other research firms also recently issued reports on GRDN. Weiss Ratings reissued a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research note on Monday, December 29th. Truist Financial upped their target price on Guardian Pharmacy Services from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, March 12th. Oppenheimer increased their target price on Guardian Pharmacy Services from $35.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Stephens raised their target price on Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, January 14th. Finally, Raymond James Financial reissued an “outperform” rating and set a $40.00 price target on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $38.00.

Guardian Pharmacy Services Stock Up 3.0%

Shares of GRDN stock opened at $35.44 on Wednesday. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of 46.02 and a beta of 0.86. The stock has a fifty day moving average of $32.25 and a 200 day moving average of $29.67. Guardian Pharmacy Services has a 52 week low of $19.17 and a 52 week high of $37.43.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings data on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.10. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The business had revenue of $397.62 million for the quarter, compared to the consensus estimate of $390.04 million. The firm’s revenue was up 17.4% on a year-over-year basis. Equities research analysts anticipate that Guardian Pharmacy Services will post 0.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Brown Advisory Inc. increased its stake in Guardian Pharmacy Services by 5.0% in the 2nd quarter. Brown Advisory Inc. now owns 1,682,476 shares of the company’s stock worth $35,854,000 after buying an additional 79,652 shares during the period. Valiant Capital Management L.P. grew its stake in Guardian Pharmacy Services by 15.8% in the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock worth $37,085,000 after acquiring an additional 167,741 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Guardian Pharmacy Services by 3.3% during the third quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock worth $30,000,000 after acquiring an additional 36,072 shares during the period. Franklin Resources Inc. increased its position in shares of Guardian Pharmacy Services by 8.2% during the third quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock worth $27,705,000 after acquiring an additional 80,033 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Guardian Pharmacy Services by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock valued at $27,675,000 after acquiring an additional 88,296 shares in the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.